Matrix metalloproteinase inhibitors - An emphasis on gastrointestinal malignancies

Critical Reviews in Oncology/Hematology

Volumn 45, Issue 2, 2003, Pages 151-176

  Chau, Ian ^a   Rigg, Anne ^a   Cunningham, David ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Cytostatic agents; Matrix metalloproteinase inhibitors; Matrix metalloproteinases; Metastasis

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; BATIMASTAT; BIOLOGICAL MARKER; CGS 27023A; CYTOSTATIC AGENT; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; PRINOMASTAT; PROTEINASE; REBIMASTAT; TANOMASTAT;

ADJUVANT THERAPY; ANGIOGENESIS; ARTICLE; CANCER CELL; CANCER GROWTH; DIGESTIVE SYSTEM CANCER; GASTROINTESTINAL TRACT; GENE THERAPY; HUMAN; METASTASIS; TUMOR REGRESSION;

EID: 0037320124     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(02)00015-X     Document Type: Review

References (147)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000-Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. 2001.
2. Office for National Statistics. Cancer Survival Trends in England and Wales 1971-1995. 1999.
3. Anderson I.C., Shipp M.A., Docherty A.J.P., Teicher B.A. Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. Cancer Res. 56:1996;715-718.
4. Foekens J.A., Portengen H., Look M.P., et al. Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer. Br. J. Cancer. 70:1994;1217-1223.
5. Grondahl-Hansen J., Christensen I.J., Rosenquist C., et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 53:1993;2513-2521.
6. Liotta L.A., Tryggvason K., Garbisa S., Hart I., Foltz C.M., Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 284:1980;67-68.
7. Stetler-Stevenson W.G. Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev. 9:1990;289-303.
8. van der Stappen J.W., Hendriks T., Wobbes T. Correlation between collagenolytic activity and grade of histological differentiation in colorectal tumors. Int. J. Cancer. 45:1990;1071-1078.
9. Bernhard E.J., Gruber S.B., Muschel R.J. Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc. Natl. Acad. Sci. USA. 91:1994;4293-4297.
10. Kawamata H., Kameyama S., Kawai K., et al. Marked acceleration of the metastatic phenotype of a rat bladder carcinoma cell line by the expression of human gelatinase A. Int. J. Cancer. 63:1995;568-575.
11. Grondahl-Hansen J., Ralfkiaer E., Kirkeby L.T., Kristensen P., Lund L.R., Dano K. Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am. J. Pathol. 138:1991;111-117.
12. Pyke C., Kristensen P., Ralfkiaer E., et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am. J. Pathol. 138:1991;1059-1067.
13. Pyke C., Kristensen P., Ralfkiaer E., Eriksen J., Dano K. The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res. 51:1991;4067-4071.
14. Pedersen H., Grondahl-Hansen J., Francis D., et al. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res. 54:1994;120-123.
15. McDonnell S., Navre M., Coffey R.J. Jr, Matrisian L.M. Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas. Mol. Carcinog. 4:1991;527-533.
16. Okada A., Bellocq J.P., Rouyer N., et al. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc. Natl. Acad. Sci. USA. 92:1995;2730-2734.
17. Pyke C., Ralfkiaer E., Tryggvason K., Dano K. Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am. J. Pathol. 142:1993;359-365.
18. Gress T.M., Muller-Pillasch F., Lerch M.M., Friess H., Buchler M., Adler G. Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int. J. Cancer. 62:1995;407-413.
19. Satoh K., Ohtani H., Shimosegawa T., Koizumi M., Sawai T., Toyota T. Infrequent stromal expression of gelatinase A and intact basement membrane in intraductal neoplasms of the pancreas. Gastroenterology. 107:1994;1488-1495.
20. Bramhall S.R., Neoptolemos J.P., Stamp G.W., Lemoine N.R. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. J. Pathol. 182:1997;347-355.
21. Itoh T., Tanioka M., Yoshida H., Yoshioka T., Nishimoto H., Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 58:1998;1048-1051.
22. Fridman R., Fuerst T.R., Bird R.E., et al. Domain structure of human 72-kDa gelatinase/type IV collagenase. Characterization of proteolytic activity and identification of the tissue inhibitor of metalloproteinase-2 (TIMP-2) binding regions. J. Biol. Chem. 267:1992;15398-15405.
23. Murphy G., Allan J.A., Willenbrock F., Cockett M.I., O'Connell J.P., Docherty A.J. The role of the C-terminal domain in collagenase and stromelysin specificity. J. Biol. Chem. 267:1992;9612-9618.
24. Sato H., Kinoshita T., Takino T., Nakayama K., Seiki M. Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2. FEBS Lett. 393:1996;101-104.
25. Sato H., Takino T., Okada Y., et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature. 370:1994;61-65.
26. Mignatti P., Rifkin D.B. Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev. 73:1993;161-195.
27. Murphy G., Atkinson S., Ward R., Gavrilovic J., Reynolds J.J. The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann. New York Acad. Sci. 667:1992;1-12.
28. Kinoshita T., Sato H., Okada A., et al. TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase immobilized on agarose beads. J. Biol. Chem. 273:1998;16098-16103.
29. Knauper V., Cowell S., Smith B., et al. The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction. J. Biol. Chem. 272:1997;7608-7616.
30. Docherty A.J., Lyons A., Smith B.J., et al. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature. 318:1985;66-69.
31. Stetler-Stevenson W.G., Krutzsch H.C., Liotta L.A. Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J. Biol. Chem. 264:1989;17374-17378.
32. Pavloff N., Staskus P.W., Kishnani N.S., Hawkes S.P. A new inhibitor of metalloproteinases from chicken: ChIMP-3. A third member of the TIMP family. J. Biol. Chem. 267:1992;17321-17326.
33. Uria J.A., Ferrando A.A., Velasco G., Freije J.M., Lopez-Otin C. Structure and expression in breast tumors of human TIMP-3, a new member of the metalloproteinase inhibitor family. Cancer Res. 54:1994;2091-2094.
34. Greene J., Wang M., Liu Y.E., Raymond L.A., Rosen C., Shi Y.E. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase. J. Biol. Chem. 271:1996;30375-30380.
35. Leco K.J., Apte S.S., Taniguchi G.T., et al. Murine tissue inhibitor of metalloproteinases-4 (TIMP-4): cDNA isolation and expression in adult mouse tissues. FEBS Lett. 401:1997;213-217.
36. Williamson R.A., Marston F.A., Angal S., et al. Disulphide bond assignment in human tissue inhibitor of metalloproteinases (TIMP). Biochem. J. 268:1990;267-274.
37. Murphy G., Houbrechts A., Cockett M.I., Williamson R.A., O'Shea M., Docherty A.J. The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry. 30:1991;8097-8102.
38. Murphy G.J., Murphy G., Reynolds J.J. The origin of matrix metalloproteinases and their familial relationships. FEBS Lett. 289:1991;4-7.
39. O'Shea M., Willenbrock F., Williamson R.A., et al. Site-directed mutations that alter the inhibitory activity of the tissue inhibitor of metalloproteinases-1: importance of the N-terminal region between cysteine 3 and cysteine 13. Biochemistry. 31:1992;10146-10152.
40. Willenbrock F., Crabbe T., Slocombe P.M., et al. The activity of the tissue inhibitors of metalloproteinases is regulated by C-terminal domain interactions: a kinetic analysis of the inhibition of gelatinase A. Biochemistry. 32:1993;4330-4337.
41. Murphy G., Willenbrock F., Ward R.V., Cockett M.I., Eaton D., Docherty A.J. The C-terminal domain of 72 kDa gelatinase A is not required for catalysis, but is essential for membrane activation and modulates interactions with tissue inhibitors of metalloproteinases. Biochem. J. 283:(Pt 3):1992;637-641.
42. Gomis-Ruth F.X., Maskos K., Betz M., et al. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature. 389:1997;77-81.
43. Overall C.M., King A.E., Sam D.K., et al. Identification of the tissue inhibitor of metalloproteinases-2 (TIMP-2) binding site on the hemopexin carboxyl domain of human gelatinase A by site-directed mutagenesis. The hierarchical role in binding TIMP-2 of the unique cationic clusters of hemopexin modules III and IV. J. Biol. Chem. 274:1999;4421-4429.
44. Wilhelm S.M., Collier I.E., Marmer B.L., Eisen A.Z., Grant G.A., Goldberg G.I. SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J. Biol. Chem. 264:1989;17213-17221.
45. Gasson J.C., Golde D.W., Kaufman S.E., et al. Molecular characterization and expression of the gene encoding human erythroid-potentiating activity. Nature. 315:1985;768-771.
46. Hayakawa T., Yamashita K., Tanzawa K., Uchijima E., Iwata K. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett. 298:1992;29-32.
47. Ritter L.M., Garfield S.H., Thorgeirsson U.P. Tissue inhibitor of metalloproteinases-1 (TIMP-1) binds to the cell surface and translocates to the nucleus of human MCF-7 breast carcinoma cells. Biochem. Biophys. Res. Commun. 257:1999;494-499.
48. Kikuchi K., Kadono T., Furue M., Tamaki K. Tissue inhibitor of metalloproteinase 1 (TIMP-1) may be an autocrine growth factor in scleroderma fibroblasts. J. Invest. Dermatol. 108:1997;281-284.
49. Albini A., Fontanini G., Masiello L., et al. Angiogenic potential in vivo by Kaposi's sarcoma cell-free supernatants and HIV-1 tat product: inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2. AIDS. 8:1994;1237-1244.
50. Anand-Apte B., Pepper M.S., Voest E., et al. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. Invest. Ophthalmol. Vis. Sci. 38:1997;817-823.
51. Johnson M.D., Kim H.R., Chesler L., Tsao-Wu G., Bouck N., Polverini P.J. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J. Cell Physiol. 160:1994;194-202.
52. Murphy A.N., Unsworth E.J., Stetler-Stevenson W.G. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J. Cell Physiol. 157:1993;351-358.
53. Schnaper H.W., Grant D.S., Stetler-Stevenson W.G., et al. Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro. J. Cell Physiol. 156:1993;235-246.
54. Takigawa M., Nishida Y., Suzuki F., Kishi J., Yamashita K., Hayakawa T. Induction of angiogenesis in chick yolk-sac membrane by polyamines and its inhibition by tissue inhibitors of metalloproteinases (TIMP and TIMP-2). Biochem. Biophys. Res. Commun. 171:1990;1264-1271.
55. Fowlkes J.L., Enghild J.J., Suzuki K., Nagase H. Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. J. Biol. Chem. 269:1994;25742-25746.
56. Koyama H., Raines E.W., Bornfeldt K.E., Roberts J.M., Ross R. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors. Cell. 87:1996;1069-1078.
57. Guedez L., Stetler-Stevenson W.G., Wolff L., et al. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J. Clin. Invest. 102:1998;2002-2010.
58. Ahonen M., Baker A.H., Kahari V.M. Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res. 58:1998;2310-2315.
59. Baker A.H., George S.J., Zaltsman A.B., Murphy G., Newby A.C. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br. J. Cancer. 79:1999;1347-1355.
60. Hida K., Shindoh M., Yasuda M., et al. Antisense E1AF transfection restrains oral cancer invasion by reducing matrix metalloproteinase activities. Am. J. Pathol. 150:1997;2125-2132.
61. Maquoi E., Noel A., Frankenne F., Angliker H., Murphy G., Foidart J.M. Inhibition of matrix metalloproteinase 2 maturation and HT1080 invasiveness by a synthetic furin inhibitor. FEBS Lett. 424:1998;262-266.
62. Eccles S.A., Box G.M., Court W.J., Bone E.A., Thomas W., Brown P.D. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res. 56:1996;2815-2822.
63. Davies B., Brown P.D., East N., Crimmin M.J., Balkwill F.R. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res. 53:1993;2087-2091.
64. Watson S.A., Morris T.M., Robinson G., Crimmin M.J., Brown P.D., Hardcastle J.D. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res. 55:1995;3629-3633.
65. Watson S.A., Morris T.M., Parsons S.L., Steele R.J., Brown P.D. Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model. Br. J. Cancer. 74:1996;1354-1358.
66. Price A., Shi Q.A., Morris D., et al. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clin. Cancer Res. 5:1999;845-854.
67. Santos O., McDermott C.D., Daniels R.G., Appelt K. Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases. Clin. Exp. Metastasis. 15:1997;499-508.
68. Gatto C., Rieppi M., Borsotti P., et al. BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity. Clin. Cancer Res. 5:1999;3603-3607.
69. Hibner B., Bull C., Flynn C., et al. Activity of the matrix metalloproteinase inhibitor BAY 12-9566 against murine subcutaneous and metastatic in vivo models. Ann. Oncol. 9:1998;283.
70. Taraboletti G., Garofalo A., Belotti D., et al. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J. Natl. Cancer Inst. 87:1995;293-298.
71. Giavazzi R., Garofalo A., Ferri C., et al. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Clin. Cancer Res. 4:1998;985-992.
72. Neri A., Goggin B., Kolis S., Brekken J., Khelemskaya N., Gabriel L. Pharmacokinetics and efficacy of a novel matrix metalloproteinase inhibitor AG3340, in single agent and combination therapy against B16-F10 melanoma tumors developing in the lung after IV tail vein implantation in C57BL/6 mice. Proc. Am. Assoc. Cancer Res. 39:1998;302.
73. Koivunen E., Arap W., Valtanen H., et al. Tumor targeting with a selective gelatinase inhibitor. Nat. Biotechnol. 17:1999;768-774.
74. Schultz R.M., Silberman S., Persky B., Bajkowski A.S., Carmichael D.F. Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16-F10 melanoma cells. Cancer Res. 48:1988;5539-5545.
75. Alvarez O.A., Carmichael D.F., DeClerck Y.A. Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases. J. Natl. Cancer Inst. 82:1990;589-595.
76. Albini A., Melchiori A., Santi L., Liotta L.A., Brown P.D., Stetler-Stevenson W.G. Tumor cell invasion inhibited by TIMP-2. J. Natl. Cancer Inst. 83:1991;775-779.
77. DeClerck Y.A., Yean T.D., Chan D., Shimada H., Langley K.E. Inhibition of tumor invasion of smooth muscle cell layers by recombinant human metalloproteinase inhibitor. Cancer Res. 51:1991;2151-2157.
78. DeClerck Y.A., Perez N., Shimada H., Boone T.C., Langley K.E., Taylor S.M. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res. 52:1992;701-708.
79. Khokha R. Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. J. Natl. Cancer Inst. 86:1994;299-304.
80. Koop S., Khokha R., Schmidt E.E., et al. Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res. 54:1994;4791-4797.
81. Montgomery A.M., Mueller B.M., Reisfeld R.A., Taylor S.M., DeClerck Y.A. Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res. 54:1994;5467-5473.
82. Imren S., Kohn D.B., Shimada H., Blavier L., DeClerck Y.A. Overexpression of tissue inhibitor of metalloproteinases-2 retroviral-mediated gene transfer in vivo inhibits tumor growth and invasion. Cancer Res. 56:1996;2891-2895.
83. Rigg A, Lemoine NR. Adenoviral delivery of TIMP 1 or TIMP 2 can modify the invasive behaviour of pancreatic cancer and prolong the survival of mice harboring a human pancreatic tumor, Cancer Gene Ther 2001;11:869-78.
84. Gore M., A'Hern R., Stankiewicz M., Slevin M. Tumour marker levels during marimastat therapy. Lancet. 348:1996;263-264.
85. Gogas H., Lofts F.J., Evans T.R., Daryanani S., Mansi J.L. Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas. Br. J. Cancer. 77:1998;325-328.
86. Halm U., Schumann T., Schiefke I., Witzigmann H., Mossner J., Keim V. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br. J. Cancer. 82:2000;1013-1016.
87. Ishii H., Okada S., Sato T., et al. CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer. Hepatogastroenterology. 44:1997;279-283.
88. Mann D.V., Edwards R., Ho S., Lau W.Y., Glazer G. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur. J. Surg. Oncol. 26:2000;474-479.
89. Hidalgo M., Eckhardt S.G. Matrix metalloproteinase inhibitors: How can we optimize their development. Ann. Oncol. 12:2001;285-287.
90. Duivenvoorden W.C.M., Hirte H.W., Singh G. Quantification of matrix metalloproteinase activity in plasma of patients enrolled in a BAY 12-9566 phase I study. Int. J. Cancer. 91:2001;857-862.
91. Stetler-Stevenson W.G. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J. Clin. Invest. 103:1999;1237-1241.
92. Fanelli M., Locopo N., Gattuso D., Gasparini G. Assessment of tumor vascularization: immunohistochemical and non- invasive methods. Int. J. Biol. Markers. 14:1999;218-231.
93. Weidner N., Semple J.P., Welch W.R., Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. New Engl. J. Med. 324:1991;1-8.
94. Fox S.B., Leek R.D., Weekes M.P., Whitehouse R.M., Gatter K.C., Harris A.L. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J. Pathol. 177:1995;275-283.
95. Axelsson K., Ljung B.M., Moore D.H., et al. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J. Natl. Cancer Inst. 87:1995;997-1008.
96. Barbareschi M., Gasparini G., Morelli L., Forti S., Dalla P.P. Novel methods for the determination of the angiogenic activity of human tumors. Breast Cancer Res. Treat. 36:1995;181-192.
97. Visscher D.W., Smilanetz S., Drozdowicz S., Wykes S.M. Prognostic significance of image morphometric microvessel enumeration in breast carcinoma. Anal. Quant. Cytol. Histol. 15:1993;88-92.
98. Wakui S., Furusato M., Itoh T., et al. Tumour angiogenesis in prostatic carcinoma with and without bone marrow metastasis: a morphometric study. J. Pathol. 168:1992;257-262.
99. Libutti S.K., Choyke P., Carrasquillo J.A., Bacharach S., Neumann R.D. Monitoring responses to antiangiogenic agents using noninvasive imaging tests. Cancer J. Sci. Am. 5:1999;252-256.
100. Leenders K.L. PET: blood flow and oxygen consumption in brain tumors. J. Neurooncol. 22:1994;269-273.
101. Mineura K., Sasajima T., Itoh Y., et al. Blood flow and metabolism of central neurocytoma: a positron emission tomography study. Cancer. 76:1995;1224-1232.
102. Schelbert H.R. Blood flow and metabolism by PET. Cardiol. Clin. 12:1994;303-315.
103. Ito K., Kato T., Tadokoro M., et al. Recurrent rectal cancer and scar: differentiation with PET and MR imaging. Radiology. 182:1992;549-552.
104. 18 F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch. Surg. 134:1999;503-511.
105. Robinson S.P., Howe F.A., Griffiths J.R. Noninvasive monitoring of carbogen-induced changes in tumor blood flow and oxygenation by functional magnetic resonance imaging. Int. J. Radiat. Oncol. Biol. Phys. 33:1995;855-859.
106. Robinson S.P., Howe F.A., Rodrigues L.M., Stubbs M., Griffiths J.R. Magnetic resonance imaging techniques for monitoring changes in tumor oxygenation and blood flow. Semin. Radiat. Oncol. 8:1998;197-207.
107. Korn E.L., Arbuck S.G., Pluda J.M., Simon R., Kaplan R.S., Christian M.C. Clinical trial designs for cytostatic agents: are new approaches needed. J. Clin. Oncol. 19:2001;265-272.
108. Erlichman C., Adjei A.A., Alberts S.R., et al. Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566. Ann. Oncol. 12:2001;389-395.
109. Hirte H., Goel R., Major P., et al. A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours. Ann. Oncol. 11:2000;1579-1584.
110. Rowinsky E.K., Humphrey R., Hammond L.A., et al. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. J. Clin. Oncol. 18:2000;178-186.
111. Herndon J.E. A design alternative for two-stage, phase II, multicenter cancer clinical trials. Control Clin. Trials. 19:1998;440-450.
112. Zee B., Melnychuk D., Dancey J., Eisenhauer E. Multinomial phase II cancer trials incorporating response and early progression. J. Biopharm. Stat. 9:1999;351-363.
113. Beattie G.J., Smyth J.F. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. Clin. Cancer Res. 4:1998;1899-1902.
114. Macaulay V.M., O'Byrne K.J., Saunders M.P., et al. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin. Cancer Res. 5:1999;513-520.
115. Parsons S.L., Watson S.A., Steele R.J. Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. Eur. J. Surg. Oncol. 23:1997;526-531.
116. Wojtowicz-Praga S., Low J., Marshall J., et al. Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Invest. New Drugs. 14:1996;193-202.
117. Millar A.W., Brown P.D., Moore J., et al. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. Br. J. Clin. Pharmacol. 45:1998;21-26.
118. Nemunaitis J., Poole C., Primrose J., et al. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin. Cancer Res. 4:1998;1101-1109.
119. Primrose J.N., Bleiberg H., Daniel F., et al. Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen. Br. J. Cancer. 79:1999;509-514.
120. Rosemurgy A., Harris J., Langleben A., Casper E., Goode S., Rasmussen H. Marimastat in patients with advanced pancreatic cancer: a dose-finding study. Am. J. Clin. Oncol. 22:1999;247-252.
121. Evans J.D., Stark A., Johnson C.D., et al. A phase II trial of marimastat in advanced pancreatic cancer. Br. J. Cancer. 85:2001;1865-1870.
122. Tierney G.M., Griffin N.R., Stuart R.C., et al. A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer. Eur. J. Cancer. 35:1999;563-568.
123. Bramhall S.R., Rosemurgy A., Brown P.D., Bowry C., Buckels J.A. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J. Clin. Oncol. 19:2001;3447-3455.
124. Fielding J., Scholefield J., Stuart R., et al. A ramdomized double-blind placebo-controlled study of marimastat in patients with inoperable gastric adenocarcinoma. Proc. Am. Soc. Clin. Oncol. 19:2000;240a.
125. Carmichael J., Ledermann J., Woll P., Gulliford T., Russell R. Phase Ib study of concurrent administration of marimastat and gemcitabine in non-resectable pancreatic cancer. Proc. Am. Soc. Clin. Oncol. 17:1998;232a.
126. O'Reilly S., Mani S., Ratain M., et al. Schedules of 5FU and the matrix metalloproteinase inhibitor marimastat: a phase I study. Proc. Am. Soc. Clin. Oncol. 17:1998;217a.
127. Jones P., Elliot M., Dobbs N., et al. Phase I/II study of combination antiangiogenesis therapy with Marimastat, Captopril and Fragmin. Proc. Am. Soc. Clin. Oncol. 18:1999;447a.
128. Miller K., Gradishar W., Schuchter S., et al. A randomized phase II pilot trial of adjuvant marimastat in patients with early breast cancer. Proc. Am. Soc. Clin. Oncol. 19:2000;96a.
129. Rasmussen H., Rugg T., Brookes C., Baillet M., Harris J. First placebo controlled safety review of marimastat: a potential new therapeutic class. Proc. Am. Soc. Clin. Oncol. 18:1999;193a.
130. Heath E.I., O'Reilly S., Humphrey R., et al. Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 48:2001;269-274.
131. Moore M.J., Hamm J., Eisenberg P.D., et al. A comparison between gemcitabine and the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. 19:2000;240a.
132. Levitt N.C., Eskens F.A., O'Byrne K.J., et al. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Clin. Cancer Res. 7:2001;1912-1922.
133. Eatock M., Cassidy J., Johnson J., et al. A Phase 1 Study of the Matrix Metalloproteinase Inhibitor MMI270 (Previously Termed CGS27023A) with 5FU and Folinic Acid. Proc. Am. Soc. Clin. Oncol. 18:1999;209a.
134. Collier M., Shepherd F.A., Ahmann F., et al. A novel approach to studying the efficacy of AG3340, a selective inhibitor of matrix metalloproteases (MMPs). Proc. Am. Soc. Clin. Oncol. 18:1999;482a.
135. D'Olimpio J., Hande K., Collier M., Michelson G., Paradiso L., Clendeninn N. Phase I study of the matrix metalloprotease inhibitor AG3340 in combination with paclitaxel and carboplatin for the treatment of patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 18:1999;160a.
136. Smylie M., Mercier R., Aboulafia D., et al. Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 20:2001;307a.
137. Ahmann F., Saad F., Mercier R., et al. Interim results of a phase III study of the matrix metalloprotease inhibitor prinomastat in patients having metastatic, hormone refractory prostate cancer (HRPC). Proc. Am. Soc. Clin. Oncol. 20:2001;174a.
138. Rudek M.A., Figg W.D., Dyer V., et al. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J. Clin. Oncol. 19:2001;584-592.
139. Ghate J.V., Turner M.L., Rudek M.A., et al. Drug-induced lupus associated with COL-3-report of 3 cases. Arch. Dermatol. 137:2001;471-474.
140. Rudek M.A., Horne M., Figg W.D., et al. Reversible sideroblastic anemia associated with the tetracycline analogue COL-3. Am. J. Hematol. 67:2001;51-53.
141. Munoz-Mateu M., de'Grafenried L., Eckhardt G., et al. Pharmacodynamic Studies of Col-3, a Novel Matrix Metalloproteinase Inhibitor, in Patients with Advanced Cancer. Proc. Am. Soc. Clin. Oncol. 20:2001;76a.
142. Daniels R., Gupta E., Kollia G., et al. Safety and pharmacokinetics of BMS-275291, a novel matrix metalloproteinase inhibitor in healthy subjects. Proc. Am. Soc. Clin. Oncol. 20:2001;100a.
143. Hurwitz H., Humphrey J., Williams K., et al. A Phase I Trial of BMS-275291: a novel, non-hydroxamate, sheddase-sparing matrix metalloproteinase inhibitor (MMPI) with no dose-limiting arthritis. Proc. Am. Soc. Clin. Oncol. 20:2001;98a.
144. Gupta E., Huang M., Mao Y., et al. Pharmacokinetic (PK) evaluation of BMS-275291, a matrix metalloproteinase (MMP) inhibitor, in cancer patients. Proc. Am. Soc. Clin. Oncol. 20:2001;76a.
145. Woessner J.F. Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 5:1991;2145-2154.
146. Goetzl E.J., Banda M.J., Leppert D. Matrix metalloproteinases in immunity. J. Immunol. 156:1996;1-4.
147. Chambers A.F., Matrisian L.M. Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst. 89:1997;1260-1270.